Hostname: page-component-7d684dbfc8-jcwnr Total loading time: 0 Render date: 2023-09-28T10:01:55.769Z Has data issue: false Feature Flags: { "corePageComponentGetUserInfoFromSharedSession": true, "coreDisableEcommerce": false, "coreDisableSocialShare": false, "coreDisableEcommerceForArticlePurchase": false, "coreDisableEcommerceForBookPurchase": false, "coreDisableEcommerceForElementPurchase": false, "coreUseNewShare": true, "useRatesEcommerce": true } hasContentIssue false
  • English
  • Français

Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data

Published online by Cambridge University Press:  05 January 2010

M. Reis  and
B. Källén
M. Reis*
Affiliation:
Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, Linköping, Sweden
B. Källén
Affiliation:
Tornblad Institute, University of Lund, Lund, Sweden
*
*Address for correspondence: Associate Professor M. Reis, Department of Forensic Genetics and Forensic Toxicology, National Board of Forensic Medicine, Artillerigatan 12, 587 58Linköping, Sweden. (Email: Margareta.Reis@med.lu.se)
Get access Rights & Permissions [Opens in a new window]

Abstract

Background

Concerns have been expressed about possible adverse effects of the use of antidepressant medication during pregnancy, including risk for neonatal pathology and the presence of congenital malformations.

Method

Data from the Swedish Medical Birth Register (MBR) from 1 July 1995 up to 2007 were used to identify women who reported the use of antidepressants in early pregnancy or were prescribed antidepressants during pregnancy by antenatal care: a total of 14 821 women with 15 017 infants. Maternal characteristics, maternal delivery diagnoses, infant neonatal diagnoses and the presence of congenital malformations were compared with all other women who gave birth, using the Mantel–Haenszel technique and with adjustments for certain characteristics.

Results

There was an association between antidepressant treatment and pre-existing diabetes and chronic hypertension but also with many pregnancy complications. Rates of induced delivery and caesarean section were increased. The preterm birth rate was increased but not that of intrauterine growth retardation. Neonatal complications were common, notably after tricyclic antidepressant (TCA) use. An increased risk of persistent pulmonary hypertension of the newborn (PPHN) was verified. The congenital malformation rate was increased after TCAs. An association between use of paroxetine and congenital heart defects was verified and a similar effect on hypospadias was seen.

Conclusions

Women using antidepressants during pregnancy and their newborns have increased pathology. It is not clear how much of this is due to drug use or underlying pathology. Use of TCAs was found to carry a higher risk than other antidepressants and paroxetine seems to be associated with a specific teratogenic property.

Keywords

Antidepressant drugscongenital malformationsneonatal symptomspregnancy
Type
Original Articles
Information
Psychological Medicine , Volume 40 , Issue 10 , October 2010 , pp. 1723 - 1733
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Alwan, S, Reefhuis, J, Rasmussen, SA, Olney, RS, Friedman, JM (2007). Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. New England Journal of Medicine 356, 2684–2692.CrossRefGoogle ScholarPubMed
Andrade, SE, McPhillips, H, Loren, D, Raebel, MA, Lane, K, Livingston, J, Boudreau, DM, Smith, DH, Davis, RL, Willy, ME, Platt, R (2009). Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiology and Drug Safety 18, 246–252.CrossRefGoogle ScholarPubMed
Bar-Oz, B, Einarson, T, Einarson, A, Boskovic, R, O'Brien, L, Malm, H, Berard, A, Koren, G (2007). Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors. Clinical Therapeutics 29, 918–926.CrossRefGoogle ScholarPubMed
Bérard, A, Ramos, E, Rey, E, Blais, L, St-Andre, M, Oraichi, D (2007). First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Research. Part B, Developmental and Reproductive Toxicology 80, 18–27.CrossRefGoogle Scholar
Chambers, CD, Hernandez-Diaz, S, Van Marter, LJ, Werler, MM, Louik, C, Jones, KL, Mitchell, AA (2006). Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. New England Journal of Medicine 354, 579–587.CrossRefGoogle ScholarPubMed
Chung, TK, Lau, TK, Yip, AS, Chiu, HF, Lee, DT (2001). Antepartum depressive symptomatology is associated with adverse obstetric and neonatal outcomes. Psychosomatic Medicine 63, 830–834.CrossRefGoogle ScholarPubMed
Cole, JA, Ephross, SA, Cosmatos, IS, Walker, AM (2007). Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiology and Drug Safety 16, 1075–1085.CrossRefGoogle ScholarPubMed
Costei, AM, Kozer, E, Ho, T, Ito, S, Koren, G (2002). Perinatal outcome following third trimester exposure to paroxetine. Archives of Pediatrics and Adolescent Medicine 156, 1129–1132.CrossRefGoogle ScholarPubMed
Davis, RL, Rubanowice, D, McPhillips, H, Raebel, MA, Andrade, SE, Smith, D, Yood, MU, Platt, R (2007). Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiology and Drug Safety 16, 1086–1094.CrossRefGoogle ScholarPubMed
Dayan, J, Creveuil, C, Herlicoviez, M, Herbel, C, Baranger, E, Savoye, C, Thouin, A (2002). Role of anxiety and depression in the onset of spontaneous preterm labor. American Journal of Epidemiology 155, 293–301.CrossRefGoogle ScholarPubMed
Dayan, J, Creveuil, C, Marks, MN, Conroy, S, Herlicoviez, M, Dreyfus, M, Tordjman, S (2006). Prenatal depression, prenatal anxiety, and spontaneous preterm birth: a prospective cohort study among women with early and regular care. Psychosomatic Medicine 68, 938–946.CrossRefGoogle ScholarPubMed
Diav-Citrin, O, Shechtman, S, Weinbaum, D, Arnon, J, Di Gianantonio, E, Clementi, M, Ornoy, A (2005). Paroxetine and fluoxetine in pregnancy: a multicenter, prospective, controlled study. Reproductive Toxicology 20, 459.Google Scholar
Diav-Citrin, O, Shechtman, S, Weinbaum, D, Wajnberg, R, Avgil, M, Di Gianantonio, E, Clementi, M, Weber-Schoendorfer, C, Schaefer, C, Ornoy, A (2008). Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. British Journal of Clinical Pharmacology 66, 695–705.Google ScholarPubMed
Dubnov-Raz, G, Juurlink, DN, Fogelman, R, Merlob, P, Ito, S, Koren, G, Finkelstein, Y (2008). Antenatal use of selective serotonin-reuptake inhibitors and QT interval prolongation in newborns. Pediatrics 122, e710–e715.CrossRefGoogle ScholarPubMed
Einarson, TR, Einarson, A (2005). Newer antidepressants in pregnancy and rates of major malformations: a meta-analysis of prospective comparative studies. Pharmacoepidemiology and Drug Safety 14, 823–827.CrossRefGoogle ScholarPubMed
Ericson, A, Källén, B, Wiholm, B (1999). Delivery outcome after the use of antidepressants in early pregnancy. European Journal of Clinical Pharmacology 55, 503–508.CrossRefGoogle Scholar
Hallberg, P, Sjöblom, V (2005). The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding: a review and clinical aspects. Journal of Clinical Psychopharmacology 25, 59–73.CrossRefGoogle ScholarPubMed
Hines, RN, Adams, J, Buck, GM, Faber, W, Holson, JF, Jacobson, SW, Keszler, M, McMartin, K, Segraves, RT, Singer, LT, Sipes, IG, Williams, PL (2004). NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of fluoxetine. Birth Defects Research. Part B, Developmental and Reproductive Toxicology 71, 193–280.CrossRefGoogle Scholar
Källén, B (1995). A birth weight for gestational age standard based on data in the Swedish Medical Birth Registry, 1985–1989. European Journal of Epidemiology 11, 601–606.CrossRefGoogle Scholar
Källén, B (2004). Neonate characteristics after maternal use of antidepressants in late pregnancy. Archives of Pediatrics and Adolescent Medicine 158, 312–316.CrossRefGoogle ScholarPubMed
Källén, B (2005). Methodological issues in the epidemiological study of the teratogenicity of drugs. Congenital Anomalies 45, 44–51.CrossRefGoogle ScholarPubMed
Källén, B (2007). The safety of antidepressant drugs during pregnancy. Expert Opinion on Drug Safety 6, 357–370.CrossRefGoogle ScholarPubMed
Källén, B (2008). Drug treatment for depression during pregnancy. In New Perspectives on Women and Depression (ed. Hansson, W. and Olsson, E.), pp. 87–108. Nova Science Publishers: USA.Google Scholar
Källén, B, Otterblad Olausson, P (2003). Maternal drug use in early pregnancy and infant cardiovascular defect. Reproductive Toxicology 17, 255–261.CrossRefGoogle ScholarPubMed
Källén, B, Otterblad Olausson, P (2006). Antidepressant drugs during pregnancy and infant congenital heart defect. Reproductive Toxicology 21, 221–222.CrossRefGoogle ScholarPubMed
Källén, B, Otterblad Olausson, P (2007). Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Research. Part A, Clinical and Molecular Teratology 79, 301–308.CrossRefGoogle ScholarPubMed
Källén, B, Otterblad Olausson, P (2008). Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiology and Drug Safety 17, 801–806.CrossRefGoogle ScholarPubMed
Levinson-Castiel, R, Merlob, P, Linder, N, Sirota, L, Klinger, G (2006). Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Archives of Pediatrics and Adolescent Medicine 160, 173–176.CrossRefGoogle ScholarPubMed
Li, D, Liu, L, Odouli, R (2009). Presence of depressive symptoms during early pregnancy and the risk of preterm delivery: a prospective cohort study. Human Reproduction 24, 146–153.CrossRefGoogle ScholarPubMed
Louik, C, Lin, AE, Werler, MM, Hernandez-Diaz, S, Mitchell, AA (2007). First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. New England Journal of Medicine 356, 2675–2683.CrossRefGoogle ScholarPubMed
Lund, N, Pedersen, LH, Henriksen, TB (2009). Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Archives of Pediatrics and Adolescent Medicine 163, 949–954.CrossRefGoogle ScholarPubMed
Malm, H, Klaukka, T, Neuvonen, PJ (2005). Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstetrics and Gynecology 106, 1289–1296.CrossRefGoogle ScholarPubMed
McElhatton, PR, Garbis, HM, Elefant, E, Vial, T, Bellemin, B, Mastroiacovo, P, Arnon, J, Rodriguez-Pinilla, E, Schaefer, C, Pexieder, T, Merlob, P, Dal Verme, S (1996). The outcome of pregnancy in 689 women exposed to therapeutic doses of antidepressants. A collaborative study of the European Network of Teratology Information Services (ENTIS). Reproductive Toxicology 10, 285–294.CrossRefGoogle Scholar
Oberlander, TF, Warburton, W, Misri, S, Aghajanian, J, Hertzman, C (2006). Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Archives of General Psychiatry 63, 898–906.CrossRefGoogle ScholarPubMed
Oberlander, TF, Warburton, W, Misri, S, Aghajanian, J, Hertzman, C (2008 a). Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study. British Journal of Psychiatry 192, 338–343.CrossRefGoogle ScholarPubMed
Oberlander, TF, Warburton, W, Misri, S, Riggs, W, Aghajanian, J, Hertzman, C (2008 b). Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Research. Part B, Developmental and Reproductive Toxicology 83, 68–76.CrossRefGoogle ScholarPubMed
Orr, ST, James, SA, Blackmore Prince, C (2002). Maternal prenatal depressive symptoms and spontaneous preterm births among African-American women in Baltimore, Maryland. American Journal of Epidemiology 156, 797–802.CrossRefGoogle ScholarPubMed
Pedersen, LH, Henriksen, TB, Vestergaard, M, Olsen, J, Bech, BH (2009). Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. British Medical Journal 339, b3569.CrossRefGoogle ScholarPubMed
Potts, AL, Young, KL, Carter, BS, Shenai, JP (2007). Necrotizing enterocolitis associated with in utero and breast milk exposure to the selective serotonin reuptake inhibitor, escitalopram. Journal of Perinatology 27, 120–122.CrossRefGoogle ScholarPubMed
Sanz, EJ, De-las-Cuevas, C, Kiuru, A, Bate, A, Edwards, R (2005). Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 365, 482–487.CrossRefGoogle ScholarPubMed
Simon, GE, Cunningham, ML, Davis, RL (2002). Outcomes of prenatal antidepressant exposure. American Journal of Psychiatry 159, 2055–2061.CrossRefGoogle ScholarPubMed
Stiskal, JA, Kulin, N, Koren, G, Ho, T, Ito, S (2001). Neonatal paroxetine withdrawal syndrome. Archives of Disease in Childhood. Fetal and Neonatal Edition 84, F134–F135.CrossRefGoogle ScholarPubMed
Suri, R, Altshuler, L, Hellemann, G, Burt, VK, Aquino, A, Mintz, J (2007). Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. American Journal of Psychiatry 164, 1206–1213.CrossRefGoogle ScholarPubMed
Toh, S, Mitchell, AA, Louik, C, Werler, MM, Chambers, CD, Hernandez-Diaz, S (2009). Selective serotonin reuptake inhibitor use and risk of gestational hypertension. American Journal of Psychiatry 166, 320–328.CrossRefGoogle ScholarPubMed
Treichel, M, Schwendener Scholl, K, Kessler, U, Joeris, A, Nelle, M (2009). Is there a correlation between venlafaxine therapy during pregnancy and a higher incidence of necrotizing enterocolitis? World Journal of Pediatrics 5, 65–67.CrossRefGoogle Scholar
Wichman, CL, Moore, KM, Lang, TR, St Sauver, JL, Heise, RH Jr., Watson, WJ (2009). Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy. Mayo Clinic Proceedings 84, 23–27.CrossRefGoogle ScholarPubMed
Wisner, KL, Sit, DK, Hanusa, BH, Moses-Kolko, EL, Bogen, DL, Hunker, DF, Perel, JM, Jones-Ivy, S, Bodnar, LM, Singer, LT (2009). Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. American Journal of Psychiatry 166, 557–566.CrossRefGoogle ScholarPubMed
Wogelius, P, Norgaard, M, Gislum, M, Pedersen, L, Munk, E, Mortensen, PB, Lipworth, L, Sorensen, HT (2006). Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 17, 701–704.CrossRefGoogle ScholarPubMed
Supplementary material: File

Reis supplementary material

Appendices.doc

Download Reis supplementary material(File)
File 193 KB